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ABSTRACT 
The adipose tissue is composed of a variety of cell types that constantly cross-communicate 
with each other to allow the tissue to operate and to adapt to various external stimuli. The 
diversity of these cell populations and their production of secretory factors define not only 
adipose tissue morphology, but also its function. This regulatory network is particularly 
important in times of adipose tissue remodeling and failure to adapt may result in severe 
malfunction of adipose tissues. Data presented in this thesis provide evidence that stromal 
vascular cells of the adipose tissue have important functions in adipose tissue remodeling and 
metabolic activation. We specifically focus on the role of various tyrosine kinase growth 
factor families such as VEGF, PDGF and FGF and their capacity to alter the adipose tissue 
microenvironment by their ability to remodel blood vessels or promote differentiation of 
vessel-associated cells into adipocytes.  
In paper I, we identified a miRNA-327-FGF10-FGFR2 autocrine regulatory loop that is 
fundamental for white adipocyte browning. We provide the first evidence that a miRNA-
dependent mechanism can control the differentiation of PDGFR-αP+ P cells into thermogenic 
beige cells. We further demonstrated that FGF10 is not only important for white adipocyte 
differentiation, but additionally possesses the ability to recruit and activate beige adipocytes. 
Finally, systemic inhibition of miRNA-327 induced white adipocyte browning, thereby 
improving whole-body metabolic rates and norepinephrine-induced thermogenesis in an 
FGF10 dependent manner. Our data suggest a therapeutic potential of FGF10 modulating 
miRNAs for treatment of obesity and related metabolic diseases.  
Paper II represents a detailed characterization of the function of VEGFR1 in the adipose 
tissue during browning and brown adipose tissue activation. Since VEGFR1 acts as a decoy 
receptor for VEGF, loss of VEGFR1 results in an increase of VEGF-VEGFR2 complex 
formation and thereby robust angiogenesis. The generation of two distinct endothelial cell 
specific knockout mouse strains allowed us to demonstrate that loss of VEGFR1 in 
endothelial cells is sufficient to induce adipose tissue angiogenesis and thereby white 
adipocyte browning and brown adipose tissue activation. Loss of VEGFR1 in adipocytes or 
myeloid cells, however, had no detectable effect on adipose tissues. Endothelial specific 
VEGFR1 KO mice were resistant to diet-induced obesity, resulting in improved insulin 
sensitivity and a reduction of ectopic lipid accumulation in the liver. Therefore, VEGFR1 
blockade in endothelial cells represents an attractive approach to treat obesity, type 2 diabetes 
and liver steatosis.  
In paper III we demonstrate that angiogenic endothelial cells produce PDGF-CC, which 
results in white adipose tissue browning. We show that such white adipose tissue browning 
can be prevented by: 1) inhibition of angiogenesis by VEGFR2 blockade, 2) systemic 
knockout of Pdgfc, or 3) by treatment with a PDGFR-α neutralizing antibody; all resulted in 
the inability of WAT to undertake a beige phenotype. We could demonstrate that endothelial 
cells influence adipocyte function in a paracrine fashion by secreting PDGF-CC that drives 
PDGFR-αP+ P preadipocytes into beige adipocyte differentiation. Hence, we conclude that an 
increase in PDGF-CC levels or the activation of PDGFR-α downstream signaling in 
preadipocytes might be a novel treatment options for obese patients.  
In paper IV we asked the question why age is such a strong indicator for obesity and insulin 
resistance, and if blood vessels play a role. We produced evidence that continuous age-related 
changes in the adipose vasculature modulate fat mass, adipocyte function, insulin sensitivity 
and blood lipid profiles. In middle-aged mice, blood vessel numbers were low and VEGFR1 
expression levels high, resulting in reduced vascular plasticity. Surprisingly, middle-aged 
mice on high-fat diet, but not standard chow, are highly sensitive to anti-VEGF treatment, 
which resulted in reduced body weight, improved HOMA-IR and enhanced glucose 
clearance. These findings indicate that low vascular plasticity in middle-aged individuals 
increases their risk to suffer from obesity and type-2 diabetes.  
Collectively, this thesis work uncovers important players in the cross talk between the 
adipose tissue vasculature and adipocytes, which lays the ground for the development of 
novel pharmaceutical approaches. 
  
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Fettvävnader är viktiga i både lagring och användning av energi, och dessa vävnader består av 
olika typer av celler som kommunicerar med varandra. Sammansättningen av vävnaden, samt 
cellernas kommunikation spelar en avgörande roll för fettvävnadens korrekta funktion. 
Samspelet definierar bland annat om fettceller hellre lagrar eller bryter ner fett, och är speciellt 
viktig t.ex. under fastande, överdrivet kaloriintag, fysisk träning eller om kroppen är utsatt för 
extremt varma eller kalla temperaturer. Komplikationer som typ 2-diabetes eller 
kardiovaskulära sjukdomar kan förekomma under sådana förhållanden om fettvävnaden inte 
kan anpassa sig. Blodkärl levererar syre och näring till cellerna och är därför viktiga för 
kommunikation mellan celler i fettvävnaden och resten av kroppen. I vår forskning försöker vi 
förstå hur blodkärl kommunicerar med omgivningen i fettvävnader under speciella 
förhållanden, med avsikten att förändra blodkärlen för att förbättra eller förhindra fetma och 
diabetes. 
I den första publikationen identifierade vi en signal – så kallad FGF10 – som är särskilt viktig 
för kommunikation i fettvävnaden när kroppen utsätts för kalla temperaturer. Genom att öka 
den signalen lyckades vi öka förmågan av fettvävnader att producera värme när möss utsattes 
för kalla temperaturer (4 °C). Intressant nog kunde vi visa att den signalen kan leda till ett ökat 
antal värmeproducerande fettceller även vid rumstemperatur. Dessa resultat är viktiga eftersom 
värmeproduktion i fettvävnaden resulterar i ökat energibehov i hela kroppen och därför 
förbrukas fler kalorier hos möss med ökad mängd av den signalen. 
I 2:a publikationen analyserade vi en signalmottagare som finns på utsidan av cellerna och 
därigenom kan ta emot signaler från andra celler. Vi upptäckte att blockering eller borttagning 
av denna mottagare resulterade i fler antal blodkärl i fettvävnaden. Genom olika experiment 
såg vi hur ett ökat antal blodkärl ledde till: 1) mer värmeproducerande celler i fettvävnader vid 
exponering för kyla, och 2) ett motstånd mot viktökning i möss som matades med kaloririk 
mat. Dessa möss hade därmed minskad risk att utveckla diabetes eller fettlever. Vi drar 
slutsatsen att blockering av denna mottagare kan vara till nytta för patienter som lider av fetma, 
typ 2-diabetes eller fettleversjukdom. 
I 3:e publikationen visar vi att celler som utgör själva blodkärlen kan producera och skicka ut 
en signal som kan förändra fettcellernas funktion. Om antalet blodkärl minskas drastiskt eller 
denna signal avlägsnas kan fettceller inte längre producera värme när möss utsätts för kyla. Om 
istället signalen är högre än normalt kan vissa celler som tätt omger blodkärlen genomgå 
förändring till att bli fettceller och därigenom producera värme.  
I 4:e publikationen studerade vi blodkärlens roll i fettvävnaden i olika åldersgrupper och kunde 
hitta skillnader i antalet av blodkärl i fettvävnader och förmåga att anpassa sig till förändringar 
beroende på ålder. Möss i medelåldern hade färre blodkärl och en minskad förmåga att ändra 
antal av blodkärl. Foder med högt kaloriinnehåll gjorde däremot fettvävnaden av möss i 
medelåldern mera anpassningsbara. Intressant nog, så ökades möjligheten av blodkärl att 
anpassa sig i möss i medelåldern med fetma drastisk, vilket resulterade i lägre kroppsvikt och 
minskad risk för att utveckla diabetes efter blodkärlsförändrande medicinering. Dessa resultat 
tyder på att minskad förmåga av blodkärl att anpassa sig till förändringar hos individer i 
medelåldern ökar risken för fetma och diabetes. 
Sammanfattningsvis avslöjar denna avhandling viktiga delar i kommunikationen mellan 
blodkärl och fettceller, som i framtiden kan ligga till grund för utvecklingen av nya läkemedel 
för att behandla fetma och relaterade sjukdomar. 
 
  
  
  
POPULÄRWISSENSCHAFTLICHE ZUSAMMENFASSUNG 
Fettgewebe besteht aus einem Gemisch verschiedener Zellarten, die miteinander 
kommunizieren. Die Zusammensetzung dieser Zellen, sowie die Art und Weise, wie sie 
miteinander kommunizieren, ist wichtig für die korrekte Funktion des Fettgewebes. Diese 
Interaktion bestimmt unter anderem, ob Fettzellen Fett speichern oder abbauen und ist 
besonders wichtig während des Fastens, übermäßiger Kalorienzufuhr, intensiver körperlicher 
Aktivität und wenn der Körper extrem heißen oder kalten Temperaturen ausgesetzt ist. Wenn 
während dieser Situationen Probleme in der Kommunikation zwischen Zellen auftreten, kann 
das Fettgewebe Schwierigkeiten haben, sich anzupassen und Komplikationen wie Typ-2-
Diabetes oder Herz-Kreislauf-Erkrankungen können auftreten. Blutgefäße versorgen die 
Zellen mit Sauerstoff und Nährstoffen und sind daher besonders wichtig für die 
Kommunikation zwischen Zellen im Fettgewebe untereinander und mit dem Rest des Körpers. 
In unserer Forschung versuchen wir zu verstehen, wie Blutgefäße mit Fettzellen 
kommunizieren. Wir versuchen außerdem diese Kommunikation so zu beeinflussen, dass 
bereits bestehende Krankheiten im Fettgewebe behoben werden können. 
In der ersten Veröffentlichung identifizierten wir einen Kommunikationsfaktor, FGF10, der 
besonders wichtig für die Anpassung des Fettgewebes an kalte Temperaturen ist. Weiters 
fanden wir einen Weg, die Menge dieses Faktors zu erhöhen, was zu einer Steigerung der 
Wärmeproduktion im Fettgewebe führte. Nicht alle Fettzellen können Wärme produzieren und 
wir konnten zeigen, dass der identifizierte Kommunikationsfaktor sogar bei Raumtemperatur 
dazu führt, dass eine erhöhte Anzahl an wärmeproduzierenden Fettzellen im Körper gebildet 
wird. Dieses Ergebnis ist wichtig, da die Wärmeproduktion im Fettgewebe zu einem erhöhten 
Energiebedarf im gesamten Körper führt. Daher können Medikamente, die diesen 
Kommunikationsfaktor aktivieren, zu potentiellem Gewichtsverlust führen.   
In der zweiten Veröffentlichung analysierten wir einen Faktor an der Zelloberfläche, der die 
Möglichkeit hat, Signale von anderen Zellen zu empfangen. Wir entdeckten, dass das 
Blockieren oder Entfernen dieses Faktors zu einer erhöhten Anzahl an Blutgefäßen im 
Fettgewebe führte. Wir setzten Mäuse, denen dieser Faktor in den Blutgefäßen fehlt, kalten 
Temperaturen aus oder fütterten diese mit kalorienreichem Futter. Die Neubildung von 
Blutgefäßen führte bei Kälteeinwirkung zu erhöhter Wärmeproduktion im Fettgewebe und zu 
einem Gewichtsverlust bei Mäusen, die mit kalorienreichem Futter gefüttert wurden. Diese 
Mäuse hatten auch ein verringertes Risiko, an Diabetes oder Fettleber zu erkranken. Wir 
schließen daraus, dass das Blockieren dieses Faktors bei Patienten mit Adipositas, Typ-2-
Diabetes oder Fettlebererkrankungen nützlich sein kann.  
In der dritten Veröffentlichung zeigen wir, dass Blutgefäßzellen einen Kommunikationsfaktor 
erzeugen und absondern können, der die Funktion von Fettzellen verändern kann. Wenn die 
Anzahl der Blutgefäße drastisch abnimmt oder dieser Faktor entfernt wird, können Fettzellen 
keine Wärme mehr erzeugen und deren Körpertemperatur nimmt ab. Wenn erhöhte Mengen 
dieses Faktors vorhanden sind, können sich Blutgefäß-assoziierte Zellen von diesen lösen und 
sich zu Fettzellen umwandeln. Dadurch wird mehr Energie in Form von Wärme vom Körper 
abgegeben, was zur Gewichtsreduktion führt. 
In der vierten Veröffentlichung definieren wir die Rolle von Blutgefäßen im Fettgewebe in 
verschiedenen Altersgruppen. Es konnten altersabhängige Unterschiede in der Anzahl und 
Anpassungsfähigkeit von Blutgefäßen festgestellt werden. Mäuse mittleren Alters hatten 
weniger Blutgefäße und eine verringerte Fähigkeit, die Anzahl der Blutgefäße zu verändern. 
Überraschenderweise machte hochkalorische Nahrung die Blutgefäße von Mäusen mittleren 
Alters anpassungsfähiger. Dadurch konnte durch medizinische Behandlung die Anzahl von 
Blutgefäßen in Mäusen mit Adipositas drastisch verringert werden, was in dieser speziellen 
Gruppe zu verringertem Körpergewicht und geringerer Wahrscheinlichkeit der Entwicklung 
von Diabetes führte. Diese Ergebnisse zeigen, dass eine verminderte Fähigkeit von 
Blutgefäßen, sich an Veränderungen anzupassen, das Risiko erhöht an Fettleibigkeit und Typ-
2-Diabetes zu erkranken. 
Zusammenfassend beschreibt diese Arbeit wichtige Akteure in der Kommunikation zwischen 
Blutgefäßen und Fettzellen, die die Basis für die Entwicklung neuer Medikamente zur 
Behandlung von Fettleibigkeit und damit verbundenen Stoffwechselerkrankungen bilden 
könnten. 
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1 INTRODUCTION 
1.1 OVERWEIGHT AND OBESITY WORLDWIDE 
Overweight and obesity is considered a 21PstP century epidemic with more than 2.1 billion people 
suffering worldwideP1P. According to the World Health Organization (WHO), overweight is 
defined as having a body mass index (BMI) greater than or equal to 25; whereas obesity is 
reached when the BMI is greater than or equal to 302. The trends of increasing body weights 
are interestingly also reflected in the population suffering from undernourishment - defined as 
insufficient energy intake resulting in a BMI less than 18.5. There has been a steady decline in 
undernourishment and a steep increase in obesity between 1990 and 2015, as shown in Fig. 13-
6.  
 
Figure 1: Obesity and undernourishment worldwide. A) Prevalence of obesity by region, measured as 
percentage of adults aged 18 years and old with BMI greater than 30 kg/m2. B) Share of population 
with caloric intake insufficient to meet the minimum energy requirements defined as necessary for a 
given population. The black triangle marks the turning point were more obese compared to 
undernourished people were observed for the first time. Data acquired from Our World in Data. Source: 
UN Food and Agricultural Organization/WHO. License: CC BY-SA3-6. 
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Obesity is associated with a great impact on the society. In fact, McKinsey company, using the 
WHO disease database, ranked obesity as one of the top three global social burdens with a 
global economic impact of 1.72 trillion € in 2012. This corresponds to 2.8% of the global gross 
domestic product (GDP) and does not take into account the large costs of treating associated 
diseases such as diabetes, cardiovascular disease and depression2. Additionally, recent 
predictions project that around 20% of the world’s population will be obese by 2025, which 
would double the economic impact7. Combined efforts are clearly needed to globally tackle 
malnutrition and reduce the burden for the individual as well as the society.  
This thesis focuses on the treatment of overweight, obesity and related diseases. Our goal is to 
generate knowledge that will help to halt, or even reverse weight gain globally and thereby 
increase quality of life for a big fraction of the world’s population.  
 
1.1.1 Obesity prevention 
Although many efforts have been made to slow down or even halt the obesity epidemics, the 
proportion of adults defined as obese has reached a devastating level worldwide, affecting 
people in both wealthy and poor countries (Fig. 2). 
 
Figure 2: Share of adults defined as obese, 2016. Percentage of defined population with BMI of 30 
kg/m2 or higher. Exact percentage in Sweden highlighted in black. Source: WHO, Global Health 
Observatory. License: CC BY-SA3-6. 
 
The fundamental cause of overweight and obesity is the imbalance between caloric intake and 
caloric expenditure. This effect can be attributed to an increased intake of energy-rich foods 
that contain high fat and high sugar, along with a decrease in physical activity, both at the 
workplace and due to improved infrastructures. 
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Being overweight or obese can have a serious impact on one’s health. Common health 
consequences of an increased BMI are an enhanced risk of chronic diseases such as 
cardiovascular diseases, diabetes, sleeping disorders, musculoskeletal disorders and some 
cancers. Many obese patients suffer from mental health problems, such as low self-esteem and 
depression, in addition to the severe physical burden (reviewed in8). 
Several daily factors are influencing how we consume and what we eat. Advertisement and 
preferential food placement of energy-rich food in stores have been shown to be linked to 
childhood obesity and food preferences in young people9. To counterbalance this, strategies to 
reduce the incidence of obesity have been developed, including: 1) regular monitoring of 
caloric intake, body weight and activity levels, 2) dietary education and control such as healthy 
diets in schools, 3) physical activity programs, and 4) higher taxes on unhealthy foods. 
However, despite these efforts, obesity incidence is still on the rise.  
Why do overweight and obesity levels still rise? One major problem is that many countries do 
not classify obesity as a disease. Therefore, people suffering from obesity do not get the 
necessary support from society and most importantly, through the health care system. It is true 
that based on the first law of thermodynamics, surplus energy uptake and insufficient energy 
expenditure over time leads to excessive accumulation of energy in the form of fat in the body 
and thereby to obesity. However, this view is too simplistic. We now know that many factors 
play determining roles in the development of obesity, such as genetic predisposition, 
environmental factors, fat distribution (waste-to-hip ratio), overall diet quality, as well as 
neuronal and endocrine communication through a variety of neuropeptides, hormones and 
growth factors that collectively are essential to control food intake and energy expenditure1.  
 
1.1.2 Metabolic syndrome 
The “metabolic syndrome” is defined as a cluster of conditions that result from excess adiposity 
and overnutrition. According to the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III (ATP III), patients are classified to have metabolic syndrome if at least 
three of the following conditions are present: hyperglycemia/insulin resistance, hypertension, 
atherogenic dyslipidemia, visceral obesity, reduced levels of low-density lipoprotein (HDL) or 
increased levels of triglycerides (TGs) in the blood10,11. The concept to define a metabolic 
syndrome is used to easily identify patients at higher risk of type 2 diabetes mellitus (T2DM) 
or cardiovascular disease (CVD), and thereby motivate patients and their physicians to take 
appropriate steps to reverse obesity (reviewed in10). 
 
1.1.3 The role of aging in obesity and metabolic disease 
Aging refers to the deterioration of homeostatic processes in the body over time, leading to 
functional decline and increased risk of disease and death. Aging is a universal contributor to 
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metabolic decline and related diseases such as T2DM, CVD and stroke12. Both, ectopic fat 
deposition and insulin resistance are closely linked to the aging process, and visceral fat 
depletion or caloric restriction have been demonstrated to improve insulin sensitivity and 
increase life span13. There are several biochemical pathways activated by caloric restriction, 
many of which alter the metabolic state of cells and activate signaling pathways important for 
glucose sensing and aging. Longevity genes are another group of genes linked to aging and 
metabolic alterations. Disruption of longevity genes such as sirtuins, p66Shc and mTOR, has 
been linked to the development of metabolic syndrome, suggesting that the loss of homeostasis 
in these signaling pathways is sufficient to cause metabolic alterations even in younger 
individuals (reviewed in14).  
One of the most important determinants of cardiovascular health is a person’s age. Beside 
pathological chances of the heart itself, impaired endothelial function can be observed in the 
aged population. Age-related pathological changes in the vasculature include atherosclerotic 
plaques, ischemic tissue and arterial stiffening caused by fibrosis, hypoxia and senescence of 
endothelial cells. Both, increased and decreased vascular density, might be detected in aging 
individuals. In patients with insufficient vascular growth or perfusion, hypertension and 
ischemic tissues are mature complications. Age-related excessive growth and remodeling, on 
the other hand, is commonly observed in the vasculature of the eye, resulting in macular 
degeneration (reviewed in15). The important angiogenic factor, vascular endothelial growth 
factor A (VEGF), together with Ang1, is particularly important in blood vessel survival and 
plasticity in adults16 and anti-VEGF is commonly used for the treatment of age-related macular 
degeneration17. Obesity and cardiovascular health are strongly linked, the effect of VEGF and 
VEGF-related signaling on age-related complications of the adipose tissue (AT), however, has 
not been studied yet in detail. It would be of great interest to determine how VEGF levels 
change during aging and how VEGF signaling can influence vascular function, metabolic 
activity and insulin sensitivity in aging ATs.  
 
1.1.4 Clinical treatment options for obesity and related diseases 
Lifestyle interventions, dietary changes and exercise are the first-line treatment choice for 
obesity18. These measures often lead to a reduction of body weight. For lifestyle interventions, 
e.g., a meaningful weight loss can be achieved, but maintaining weight loss over time has 
proven itself difficult19. Medical or surgical interventions are clinically approved in addition to 
the previous measures and are reserved for patients with moderate- to high-risk obesity that 
show comorbidities or have failed to reduce their weight by first-line interventions20. Drugs 
that are food and drug administration (FDA) approved for the treatment of obesity either inhibit 
lipid uptake in the intestine (e.g. Orlistat) or reduce appetite and food intake (e.g. Lorcaserin 
and Liraglutide). These drugs result in an average weight loss of less than 10%1. Bariatric 
surgery, on the other hand, a surgical procedure with the purpose to restrict the amount of food 
the stomach can hold, is much more effective, with an average weight loss of 23% after a 2 
year period21. Surgery also positively affects a number of comorbidities such as T2DM and 
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sleep apnea and patients report a consistent improvement in quality of life1. Most of the surgical 
procedures are however permanent and possible long-term consequences such as fat 
malabsorption, protein-energy malnutrition and micronutrient deficiencies can occur, resulting 
in potential life-long requirement of oral supplementations22. While surgery is still the best 
option for patients with obesity, there is a strong need to develop novel, non-invasive, and more 
efficient drugs. Understanding the AT and pathological changes during obesity are essential to 
reach this goal. One promising novel approach is the conversion and activation of white 
adipocytes (WAs) into metabolically more active beige adipocytes (ACs) together with the 
activation of preexisting brown adipocytes (BAs). The following chapter will explain the 
different types of ACs and their function in energy storage, heat production and cell-cell 
communication. 
 
1.2 ADIPOSE TISSUE 
AT is a type of loose connective tissue that contains ACs; cells specialized in storing energy in 
form of triglycerides. In mammals, AT is mainly located subcutaneously, adjacent to organs 
and in the bone marrow23. For many years, it was believed that AT was solely important for 
insulation, mechanical support, and energy storage in times of surplus and energy source in 
times of starvation. However, since the discovery in 1994 that leptin is exclusively produced 
and secreted by ACs24, it is recognized and classified as an endocrine organ. A great number 
of AT-derived secretory factors have since been identified, including cytokines, metabolites, 
hormones and growth factors25. With recent knowledge, it has become clear that ATs are 
critically involved in the regulation of energy homeostasis, the immune system, wound healing, 
reproduction and blood vessel biology26.  
 
1.2.1 Energy storage and heat production 
There are two types of ACs, white and brown ACs. White ACs have leptin as their 
characteristic protein. Their main function is energy storage, which is accomplished by a 
centrally contained single lipid droplet. Histologically, their nucleus and cytoplasmic content 
is pushed towards the cell wall; therefore, their appearance is white under the light microscope. 
Brown ACs, on the contrary, have multiple smaller lipid droplets, abundant mitochondria and 
uncoupling protein 1 (UCP1) as their characteristic protein27,28. Their high mitochondrial 
content let them appear brown under the light microscope and their main function is to use 
energy to produce heat by a process called thermogenesis29. Brown AT (BAT) exists at many 
sites in most new-born mammals, but can even be found at later age, especially in hibernating 
animals30 and rodents31. With the help of fluorodeoxyglucose-positron emission tomography / 
computer tomography (FDG-PET/CT), active and functional BAT was recently detected and 
characterized in adult humans32. First clinical studies demonstrated that activation of 
thermogenesis in humans increases resting metabolic rates by around 200 kcal/day and 
significantly improves insulin sensitivity33. Since then, BAT is recognized as powerful novel 
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therapeutic target for the treatment of a variety of metabolic diseases34. In addition to BAT, a 
subset of WA has the ability to increase their mitochondrial content and act as thermogenic 
cells. These cells are commonly known as beige ACs and evolve within white adipose depots35. 
Due to the limited amount of BA in adult humans, additional WA activation might be necessary 
to achieve desired clinical outcomes36. A more detailed characterization of beige and brown 
AT development and activation is however essential to overcome current therapeutic 
challenges such as the identification of the most beneficial method of BAT activation for the 
treatment of obesity and T2DM as well as the reduction of cardiovascular side effects33. 
 
1.2.2 White fat browning 
Browning is the process in which beige ACs are generated in WAT following stimuli such as 
cold temperature, adrenergic activation or exercise37. These beige ACs can be generated by 
both de novo differentiation of preadipocytes38 and transdifferentiation of preexisting WAs and 
are characterized by a distinct morphology with a more centralized nucleus, multilocular lipid 
droplets as well as an increase in mitochondrial number and activity (reviewed in37). An 
essential function of beige ACs is the ability to, upon adrenergic stimulation, activate UCP1 
expression. UCP1 is located in the inner membrane of mitochondria and is essential for the 
generation of heat by a process called non-shivering thermogenesis. This process leads to a 
reduction of ATP production in the mitochondria and thereby to increased energy requirements 
in order to maintain the cell’s energy needs39.  
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) - probably 
the most important regulatory protein in thermogenesis - can activate the expression of UCP1 
and key mitochondrial enzymes when ectopically introduced into WAs40. Physiologically, 
PGC-1α is activated upon adrenergic stimulation when norepinephrine (NE) binds to the β3-
adrenergic receptor (β3-AR) on ACs. A large number of browning factors, which are factors 
that enhance beige AC number, have been identified. Some examples are: 1) myokines that are 
activated downstream of PGC-1α upon exercise (e.g. irisin and β‐aminoisobutyric acid); 2) 
factors that regulate UCP1 synthesis (e.g. thyroid hormones); 3) proteins involved in 
adipogenesis (e.g. bone morphogenic proteins (BMPs) and diverse growth factors); 4) 
molecules that act in the central nervous system (e.g. leptin and melatonin) or; 5) other factors 
involved in one of the many steps required for beige AC differentiation and activation 
(reviewed in41).  
If any of these factors will be powerful and specific enough to treat metabolic disorders in 
humans, however, remains unclear. 
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1.2.3 Adipogenesis and adipose tissue maintenance 
ACs are derived from mesenchymal stem cells (MSCs) that first commit to precursor cells, 
then preadipocytes and lastly to terminally differentiated mature ACs in a process called 
adipogenesis42. 
MSCs are multipotent stromal cells that have the ability to become osteoblast, chondrocytes, 
myocytes and ACs43,44. All white precursor cells are myogenic factor 5 negative (Myf5-) MSC. 
Dr. Cannon’s research group could however demonstrate that brown AC precursors harbour 
myogenic gene expression patterns like Myf5 and can commit to both the fate of myoblasts 
and brown preadipocytes45, suggesting distinct origins for white compared to brown ACs. It 
was further demonstrated that the expression level of ccaat-enhancer-binding protein (C/EBP-
β) and PR domain containing 16 (PRDM16) determines if Myf5+ cells commit to brown 
preadipocytes or myoblasts27.  
For both, white and brown ACs, further commitment to preadipocytes seems to be regulated 
by transforming growth factor-β (TGF-β) family proteins, such as BMP7 in brown 
progenitors46 or BMP247 and BMP448 in white progenitors. A complex interplay of 
transcription factors and signalling pathways are typically in place to allow preadipocytes to 
further differentiate into mature ACs42. Studies in preadipocyte cell lines demonstrated that 
hormonal induction of AC differentiation was followed by expression of the early 
differentiation factors C/EBPβ and C/EBPδ which induce the transcription of C/EBPα and 
peroxisome proliferator-activated receptor gamma (PPARγ)49. The latter two factors transform 
the cells into mature ACs and stay active for the life of the AC50. Further studies showed that 
PPARγ alone can initiate the adipogenic program and retroviral overexpression results in cells 
that possess many features of mature ACs51,52. Additionally, PPARγ could induce adipogenesis 
in C/EBPα deficient mouse embryonic fibroblasts (MEFs). Therefore PPARγ can be seen as 
the proximal effector in AC differentiation50. In addition to these transcription factors, a variety 
of signalling pathways such as insulin-like growth factor, platelet-derived growth factor 
(PDGF), fibroblast growth factor (FGF), wingless/integrated (Wnt) - β-catenin and hedgehog 
(Hh) have been identified to be crucial to control preadipocytes commitment to mature 
ACs42,53.  
Whether or not ACs of different depots need distinct signals to differentiate, and how many 
steps MSCs have to undergo to differentiate into mature ACs, is not yet clear. The reason being 
a limited number of cell-specific markers and a lack of unique morphological characteristics in 
progenitor cells and preadipocytes53. 
 
1.2.4 Plasticity in the adipose tissue 
In obese individuals, body fat mass can reach up to 40% of whole-body composition54. 
Adipocyte size, however, doesn’t increase linearly with obesity level but rather shows large 
inter-individual variations55. The cellular and molecular mechanisms controlling AC size and 
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AT growth in different individuals are largely unknown, it is however well understood that AC 
hypertrophy is associated with metabolic complications, independent of body composition and 
fat distribution56. An elegant approach developed by Peter Arne’s research group revealed that 
the turnover rate of ACs in adult humans is about 10% per year55. In mice, this number is 
estimated to be around 10-15% per month, which reflects a slightly higher turnover rate in mice 
compared to humans considering the shorter lifespan of mice57. In addition, turnover rates are 
sensitive to pharmacological, physiological and dietary stimuli58. Inducible genetic depletion 
of all mature AC in mice demonstrated further, how plastic adult AT is. Depleted ACs could 
completely regenerate within weeks59. This enormous plasticity generates a promising niche 
for clinical interventions and gives hope to people suffering from metabolic diseases. 
 
1.3 ADIPOSE TISSUE VASCULATURE 
Vascularization defines the growth and function of all tissues and organs. The delivery of 
oxygen and nutrients as well as the removal of waste products are strongly dependent on blood 
vessel number and organisation. Hormones and growth factors delivered through the blood 
stream effect AT function and AC activation60. The interplay between AT vasculature and ACs 
is specifically interesting because AT is very plastic throughout adult life and this plasticity is 
strongly dependent on its vasculature61-64. The increase in volume of pre-existing AC 
(hypertrophy) and the formation of new small ACs (hyperplasia), for example, are tightly 
linked to blood vessel structure and angiogenesis65. Vascularisation develops in concert, or 
even guide adipogenesis66. The importance of blood vessels in AT can be further reflected by 
the fact that every AC is in direct contact with a blood vessel at all times. Consequently, AT 
represents one of the most vascularized organs of the human body67. Furthermore, there is a 
strong correlation between vessel density and metabolic activity in ACs. Increasing blood 
vessel number in AT alone is sufficient to increase AC metabolism and leads to a brown-like 
phenotype in WAT. Blocking angiogenesis, on the other hand, will block AC browning64. 
It has been postulated for decades that adipocyte progenitor cells (APCs) are located in the 
proximity of blood vessels68, however only recent lineage tracing approaches could verify that. 
Perivascular smooth muscle cells69, fibroblasts38 and pericytes70 are able to differentiate into 
ACs in vivo. Especially cells derived from the stromal vascular fraction (SVF) with high 
expression levels of cluster of differentiation 34 (CD34), PDGFR-α and stem cell antigen 1 
(Sca1) display a high potency to differentiate into ACs. Additional markers, such as CD24, 
neuron-glial antigen 2 (NG2), smooth muscle actin (SMA) and PDGFR-β can be expressed on 
APCs and might help to understand tissue specific differences in preadipocyte populations 
(reviewed in71).  
Through such experiments, it is clear that blood vessel number and organisation play a crucial 
role in adipogenesis and AT remodelling. Understanding the crosstalk between ACs and AT 
vasculature is crucial as large AC size, defective blood vessels and low metabolic activity in 
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the AT correlate with dysfunction and metabolic disease. Therefore, a healthy vascular network 
in AT is crucial for metabolic health54. 
 
1.3.1 Adipocyte-vascular crosstalk 
The AT SVF cell population includes endothelial cells, fibroblasts, B- and T-lymphocytes, 
macrophages, myeloid cells, pericytes, smooth muscle cells, and adipose stromal/stem cells 
72.  Different cell types in the AT communicate with each other via cell-cell contact or by 
secreting factors such as cytokines73, hormones and growth factors74. Several proteomic 
profiling approaches have recently been performed to define the complete secretome of the AT 
and around 600 secretory factors have been identified so far75. Adipose-derived secretory 
factors modulate adipogenesis76, immune cell recruitment and activation77, as well as AC 
metabolism and function78. Crucial adipokines secreted by ACs, such as leptin and adiponectin, 
are widely studied and their functions and expression patterns have been characterized in 
detail79. Interestingly, however, ACs only make up less than 50% of cells in the AT80. 
Moreover, WAT expansion and remodelling leads to changes in progenitor cell population and 
cell composition in the AT81. Only a few studies have addressed the question how SVF cells 
respond to alterations in AC metabolism and tried to explain the crosstalk between different 
cell types in the AT.  
The following chapters describes the interplay between ACs and vascular cells in the AT. A 
special focus will be directed to vessel modulating adipokines and important growth factor 
families such as VEGF, FGF and PDGF families. 
 
1.3.2 The impact of adipokines on the vasculature 
Adipokines are defined as biologically active molecules that are secreted by the AT and 
involved in various processes within the AT as well as systemically82.  
One of the most studied adipokines is adiponectin - a protein hormone critically involved in 
glucose and lipid homeostasis – with important additional effects being exerted directly on the 
vasculature. It acts through binding to its cell surface receptors; Adiponectin receptor 1 
(AdipoR1) (skeletal muscle), AdipoR2 (liver), and T-cadherin (cardiovascular system)83. 
Circulating in the bloodstream, adiponectin protects the endothelium and has strong anti-
inflammatory properties84. It can further promote endothelial progenitor cell migration upon 
vascular damage, reduce the production of reactive oxygen species, and thereby diminish 
oxidative stress85. In contrast to the majority of adipokines, adiponectin levels are inversely 
correlated to body weight86. Furthermore, high adiponectin levels are linked to lower risk of 
hypertension87. Therefore, adiponectin can be considered as one of the beneficial adipokines. 
Adding to the list of adipokines with beneficial effects are; omentin - an adipokine that induces 
insulin-mediated signalling, and whose expression is negatively correlated to BMI and 
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coronary atherosclerosis88, and apelin - which has a positive effect on the aortic wall, causing 
its relaxation89.   
In contrast, there are also several adipokines that are harmful for the vasculature. Leptin, for 
example, represents a strong risk factor for atherosclerosis90 and thrombosis91 and has pro-
inflammatory properties by increasing C-reactive protein (CRP) transcription92. The primary 
function of leptin is to regulate food intake and energy expenditure. In obese patients, a 
resistance to leptin is gradually acquired, resulting in an inability to feel sated. Adipocyte fatty 
acid binding protein (A-FABP) is a pro-inflammatory cytokine. It is upregulated in obese 
individuals and strongly linked to vascular dysfunction. High A-FABP levels lead to 
endothelial dysfunction, atherosclerosis, hypertension, and coronary heart disease93. Other 
adipokines related to cardiovascular disease include resistin, a pro-thrombotic adipokine94 and 
chimerin, which has been linked to early atherosclerotic plaque formation95. 
 
1.4 ADIPOSE TISSUE GROWTH FACTORS 
1.4.1 VEGF signaling and angiogenesis in adipose tissues 
The VEGF growth factor family consists of VEGF, VEGF-B, VEGF-C, VEGF-D, and 
placental growth factor (PlGF) and the corresponding tyrosine-kinase receptors VEGFR1, 
VEGFR2 and VEGFR3. In some cases, neuropilins (NRPs) can act as co-receptors by 
interacting with heparin binding VEGF isoforms and PlGF. VEGF, VEGF-B and PlGF are 
further alternatively spliced and exist in soluble and heparin binding forms. They bind the 
receptors as homodimeric polypeptides, although naturally occurring heterodimers of VEGF 
and PlGF have been described96. 
Signals are transmitted when VEGF ligands bind to their corresponding receptors, resulting in 
receptor dimerization and conformational changes in the receptor monomers97. The ATP 
binding site in the intracellular kinase domain gets exposed, followed by binding of ATP and 
auto- or transphosphorylation of the tyrosine residues on the receptor itself or downstream 
signal transducers98. The signal transduction is tightly controlled by dephosphorylation or 
internalization and degradation of the receptors99.  
Activation of different VEGFR by specific ligands leads to distinct outcomes. When VEGFR1 
interacts with VEGF-B or PlGF, it has an important role in tissue homeostasis and 
regeneration100. VEGF has around 10-times higher binding affinity for VEGFR1 compared to 
VEGFR2. Due to the weak tyrosine-kinase activity of VEGFR1, angiogenesis is inhibited when 
VEGF binds to VEGFR1 instead of VEGFR2. Therefore VEGFR1 is sometimes referred to as 
“decoy” receptor for VEGF101. The interaction of VEGF with VEGFR2 however, results in 
robust vasculogenesis during embryonic development and angiogenesis in adults102. VEGFR3 
is the main growth factor receptor controlling lymphangiogenesis by interaction with VEGF-
C and VEGF-D103,104.  
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Figure 3: VEGF signaling. Representation of the interaction between VEGF ligands and their 
receptors and possible functional outcomes. 
 
In the AT, VEGF-A mainly originates from ACs and adipose specific depletion of VEGF 
results in reduced vascular density, hypoxia, apoptosis, inflammation and metabolic defects in 
mice fed with high fat diet (HFD)105. Overexpression, on the other hand, results in increased 
adipose vasculature, reduced hypoxia and reversed metabolic defects in mice fed on HFD105. 
A doxycycline inducible mouse model further demonstrated that adipose specific 
overexpression of VEGF results in rapid browning and increases fat graft survival and 
activation106. 
As mentioned previously, VEGFR1 acts as a counter player to VEGFR2. Overexpression of 
VEGF-B resulted in increased VEGF /VEGFR2 signalling and angiogenesis in ATs and 
depletion of VEGFR1 further promoted this effect, resulting in increased AT function in obese 
mice107. This suggests VEGF-B/VEGFR1 as a therapeutic target to increase vascular density 
and AC metabolism in order to counteract obesity and diabetes. 
Lymphatic vessels have an essential role in lipid transport108 and immune cell trafficking109. 
How these vessels influence adipose metabolism, however, is not fully understood110. VEGF-
C and VEGF-D levels have been correlated to obesity and unfavourable lipid parameters. 
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Therefore, Michael Detmar’s research group utilized a soluble VEGFR3 (acting as a ligand 
scavenger) overexpressing mouse model to demonstrate that decreased VEGFR3 signalling 
and resulting decreased lymphatic vessel numbers protect against obesity-induced insulin 
resistance and hepatic lipid accumulation111. To further evaluate their findings, VEGF-C 
overexpressing mice were generated. Increased levels of VEGF-C resulted in weight gain, 
insulin resistance and ectopic lipid accumulation112. In both cases the effect could be linked to 
macrophage polarization and number111,112. Therefore, it can be concluded that VEGFR3 
mediated lymphangiogenic signalling is unfavourable in obese patients and attenuation of it 
could be a promising strategy to improve diabetes and metabolic syndrome. VEGFR3 
signalling was described to provide a holistic view on the VEGF signalling family, lymphatic 
vessel biology is, however, outside the scope of this thesis and will not be discussed further. 
 
1.4.2 PDGF signaling and adipocyte progenitor cell fate 
The PDGF family consists of four ligands (PDGF-A, PDGF-B, PDGF-C and PDGF-D) that 
act via two receptor tyrosine-kinases (RTKs), PDGFR-α and PDGFR-β113. The possible 
PDGF-PDGFR interactions include homo- and heterodimer formation of both ligands and the 
receptors and are multiple and complex. How many of these combinations are physiologically 
relevant, however, is still unclear. Knockout of PDGF receptors in mice demonstrated that 
PDGFR-β and PDGF-B are essential for the development of perivascular cells, whereas 
PDGFR-α and PDGF-A are more broadly required for successful embryogenesis114.  
PDGFR-β could be identified as marker for proliferating and renewing adipogenic progenitors. 
PDGFR-β+ cells are located in the perivascular niche and contribute to WA development in 
vivo115. Additionally, in 2012, PDGFR-α+ cells were defined as bipotential AC progenitor cells 
that can differentiate into both BA and WA, suggesting a role for both PDGFR-α and PDGFR-
β in adipogenesis116. In adult mice, PDGFR-β+ cells seem to differentiate into ACs when 
challenged with HFD or adrenergic stimulation70.  If PDGF signalling is over-stimulated, 
however, these cells are forced to differentiate into fibroblasts instead of pericytes or ACs117. 
This has been observed in obese patients. Onogi et al. described that despite the physiological 
role of PDGF-BB-PDGFR-β+ in AT neovascularization and pericyte recruitment, the increased 
recruitment of PDGF-B expressing pro-inflammatory M1-macrophages in obese patients can 
lead to pericyte detachment and fibrosis117. This observation could be repeated by increasing 
PDGFR-α kinase activity in mice, which resulted in severe perivascular fibrosis and failure to 
develop WAT118. This demonstrates that both increased PDGFR-α and PDGFR-β signalling 
forces progenitor cells to differentiate into fibroblasts.  
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Figure 4: PDGF signaling. Representation of the interaction between PDGF ligands and their 
receptors and possible functional outcomes. 
 
Traditionally, PDGFR-β is defined as mural cell marker119, and PDGFR-α as fibroblast 
marker116, but their similar mesenchymal phenotype and plastic receptor expression patterns 
(sometimes both PDGFR-α and PDGFR-β can be found on the same cell and might even 
heterodimerize120), do not allow cell type classification based on PDGFR expression only. A 
recent study demonstrated that PDGFR-α expression precedes PDGFR-β expression in 
subcutaneous adipose depots, but only in a small subset of visceral adipose stromal cells, 
suggesting additional tissue specific differences. A recent study could confirm that HFD 
feeding or thermoneutrality increased the recruitment and differentiation of PDGFR-β+ cells 
into ACs and resulted in bigger ACs and obesity. This study could further demonstrate that 
depletion of PDGFR-β+ cells, on the other hand, protected against diet induced obesity 
(DIO)121. Future research will help to further define the physiological functions of PDGFs and 
PDGFRs in adipose derived MSCs and adipose progenitor cells and will hopefully clarify the 
fate of PDGFR-α+ and PDGFR-β+ cells in distinct ATs in vivo. 
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1.4.3 FGFs that act as adipokines 
The FGF family comprises 22 members with high sequence similarity, however, diverse 
mechanisms of action. Most FGFs are canonical FGFs that act as extracellular proteins binding 
one of the four FGFRs (FGFR1-4) and function in either paracrine or endocrine manner. 
FGF11-14, however, are intracellular FGFs that act independently of receptor binding122. All 
four receptors contain three extracellular immunoglobulin-like domains IgI, IgII, and IgIII that 
are important in receptor dimerization. FGFR1–3 can alternatively use part of the IgIII domain 
to generate FGFR1-3a, b and c isoforms that are expressed in different tissues and have distinct 
binding specificities123. 
Knockout (KO) studies in mice have shown that FGFs are important for early embryonic 
development and organogenesis. In adult tissues, they mediate metabolic functions, tissue 
repair and regeneration124. Three FGFs have been identified as adipokines; FGF1, FGF10 and 
FGF21. FGF1 binds to all FGFRs and has been demonstrated to be highly induced in WAT 
upon HFD feeding. Furthermore, the PPARγ-FGF1 axis has been shown to be critical for 
maintaining metabolic homeostasis and insulin sensitization. FGF1 KO mice are viable, but 
display severe insulin resistance, inflammation, vascular defects and aberrant AC size 
distribution upon HFD feeding125.  
FGF10 is another adipokine that binds with high affinity to FGFR-2b in the target tissue. 
FGF10 KO mice die shortly after birth due to multi-organ failure126. FGF10 is abundantly 
expressed in WAT, especially by preadipocytes, and loss of this factor in vivo results in reduced 
proliferation of preadipocytes and great impairment of WAT development127,128. 
FGF21, which binds FGFR-1c, mainly acts as a hepatokine and is involved in glucose and lipid 
metabolism. Fasting or ketogenic diet increases FGF21 expression, resulting in augmented 
glucose and lipid metabolism in hepatocyte and WAs. FGF21 transgenic mice are resistant to 
DIO. Furthermore, administration of recombinant FGF21 to ob/ob (leptin deficient) and db/db 
(leptin receptor deficient) mice reduces their glucose levels to near normal levels129,130 by 
inducing PPARγ and thereby promoting insulin sensitivity131. In addition, FGF21 is 
synthesized in BAT in response to cold exposure where it activates mitochondrial 
uncoupling132.  
Collectively, these findings suggest FGFs and downstream signalling as potential novel targets 
for therapeutic interventions for the treatment of obesity, diabetes and related metabolic 
diseases. 
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1.5 MICRORNAS IN ADIPOSE CONTEXT  
1.5.1 What are microRNAs? 
The cell has developed intricate strategies to regulate and fine-tune its transcriptional output. 
One of these strategies are noncoding or non-messenger RNAs, a group of diverse molecules 
with structural, enzymatic and regulatory functions. MicroRNAs (miRNAs) belong to the 
group of small non-coding RNA molecules, are about 22 nucleotides in length and have been 
shown to regulate RNA silencing and control post-transcriptional regulation of gene expression 
(reviewed in133). 
. 
 
Figure 5: MiRNA synthesis and target interaction. Representation of the miRNA synthesis process and 
relocation to the cytoplasm that allows target silencing. 
 
MicroRNAs themselves are transcribed by polymerase II or polymerase III to primary 
transcripts (pri-miRNAs) in the nucleus. Drosha and its co-factor DiGeorge syndrome critical 
region gene 8 (DGCR8) cleave pri-miRNAs at the bottom of their stem loops to 70-nucleotide 
precursors (pre-miRNAs). Exportin5 is responsible for their export to the cytoplasm where 
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Dicer generates a 20-25 nucleotide long miRNA duplex. The active strand of the miRNA 
duplex is retained in the RNA-induced silencing complex (RISC) to base pair with target 
mRNAs leading to Argonaut-dependent mRNA cleavage or translational repression134. Figure 
5 shows a simplified schematic of the process by which miRNAs are generated. Since the 
discovery of the first miRNA in 1993135, hundreds of miRNAs have been identified that directly 
regulate the expression of over 30% of human and mouse genes and 60% of human protein-
coding genes have been under selective pressure to maintain a conserved sequence in the 3’ 
untranslated region (UTR) to base pair with miRNAs136. 
 
1.5.2 MiRNAs in adipogenesis, browning, and metabolic disease 
To define the function of miRNAs in AT development, adipose specific Dicer KO mice were 
generated. These mice had defects in WAT development and reduced thermogenic activity in 
BAT and died within three weeks after birth137. In contrast, KO of Dgcr8 in all adiponectin 
positive cells resulted in a viable and fertile mouse strain that demonstrated defects in brown 
fat development and browning, suggesting that miRNAs are especially important to 
metabolically highly active brown and beige ACs138. MiR-133 and miR-155 have since been 
identified to negatively regulate BA differentiation and browning in vivo139,140. On the contrary, 
the miR-193b-365 cluster and miR-196a induce BA differentiation and WA browning141,142. 
This highlights that different miRNAs, depending on the specific targets, will have a unique 
impact on AT differentiation and browning. Thus, every single miRNA must be evaluated 
separately to draw conclusions. 
In DIO, a subset of miRNAs is deregulated in both human and mice. These miRNAs vary 
drastically between different depots; however, they mainly seem to be involved in immune 
response, lipolysis and AC differentiation143-145. Furthermore, significant positive correlation 
between the upregulation of a subset of miRNAs and insulin resistance could be revealed in 
obese patients146. Therefore, it is reasonable to speculate that miRNAs have pathophysiological 
functions, and might be associated with impaired adipogenesis, insulin resistance and obesity-
related inflammation. This suggest miRNAs as viable targets to combat T2DM and other 
metabolic complications associated with obesity. 
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2 AIMS 
The overall aim of this thesis was to define the role of growth factor signaling and angiogenesis 
in AT activation, metabolic disease and aging. 
The specific aims were: 
I: To define the function of growth factor targeting miRNAs in AT browning 
II: To characterize the role of VEGFR1 in AT browning and metabolic disease 
III: To identify SVF-derived secretory factors that induce AT browning  
IV: To evaluate age-related changes in the adipose vasculature and their consequences on AC 
function. 
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3 RESULTS AND DISCUSSION 
Blood vessels are not solely important for coping with metabolic changes in the AT, they also 
play a prominent role in modulating adipocyte function67. By secreting paracrine factors, ECs 
communicate directly with ACs to e.g. activate them during adrenergic stimulation63. A 
collection of studies further demonstrated that perivascular cells serve as the progenitor pool 
for ACs and control AT plasticity115,121,147. The publications included in this thesis focus on the 
role of blood vessels in the regulation of AC differentiation and function. 
 
3.1 PAPER I: A MIR-327-FGF10-FGFR2-MEDIATED AUTOCRINE SIGNALING 
MECHANISM CONTROLS WHITE FAT BROWNING  
Many stimuli such as cold exposure, adrenergic activation, exercise, and diet have been 
identified that have the ability to activate WAs to take on a brown-like phenotype148. The 
molecular mechanisms why some cells are recruited and commit to a beige adipose lineage, 
however, are not fully understood. One group of possible modulators of AC differentiation 
are miRNAs – small non-coding RNAs that have a function in RNA silencing and post-
transcriptional gene regulation. Overexpression of miRNAs that target important regulators 
of adipocyte differentiation such as C/EBPβ resulted in a substantial reduction of fat mass in 
vivo139, proving evidence for their ability to alter differentiation potential in ACs. 
In this publication, the aim was to identify secretory factors that have the ability to drive ACs 
into differentiation under browning conditions and find molecular regulatory mechanisms 
that lead to their activation. Therefore, we performed microarray analysis in parallel to a 
miRNA array on SVF-derived cells from browning WAT. We could identify a group of 
growth factors that were upregulated upon browning and corresponding downregulated 
miRNAs that target these growth factors. Several members of the FGF family were induced 
in the SVF of browning WAT and we could successfully identify miR-327 as a miRNA that 
targets FGF signaling and is suppressed during adrenergic stimulation. FGF10-FGFR2 
signaling drives preadipocytes into differentiation and we could demonstrate that miR-327 
controls this process by modulating FGF10 levels, both in vitro and in vivo. In vivo, blockade 
of miR-327 increased FGF10 levels in WATs and resulted in a reduction of adipocyte size 
and induction of UCP1 expression. Genetic diminishment of FGF10 by utilizing Fgf10+/- 
mice blocks the miR-327 inhibitor-induced activation of WAT, suggesting FGF10 as the 
mature effector in this process. Our data suggest an autocrine regulatory pathway in 
preadipocytes of WAT where miR-327 expression levels control FGF10 protein levels and 
thereby downstream FGFR2 signaling, adipocyte differentiation and browning. 
In more details, our first approach was to set a time-point during the treatment with the β3-
adrenergic receptor agonist CL 316,243 (from now on referred to as CL) and the exposure to 
cold, where both angiogenesis and AC browning are already detectable in WAT but 
remodeling still occurs. Only 5 days of CL treatment and 2 weeks of 4°C exposure were 
sufficient to substantially activate both angiogenesis and white AC browning in scWAT and 
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visWAT, with augmented amounts of mitochondria and UCP1 in AC and increased numbers 
of ECs and perivascular stromal fibroblasts present in the browning tissues. Therefore, we 
chose these two time points for all following in vivo functional analysis. We know from 
previous studies that the expression levels of a number of secretory factors peak at around 1-
5 days of CL treatment and thereafter return to their physiological levels62,63. Thus, we 
performed miRNA array analysis on 3-day CL treated SVFs of visWAT compared to vehicle 
treated controls. From a number of up-, and downregulated miRNAs, we extracted growth 
factor targeting, downregulated miRNAs and confirmed their expression levels by qPCR 
analysis. Targets were identified with a number of online tools such as miRWalk, TargetScan 
and microRNA.org. One of the most downregulated miRNAs, miR-327, was predicted to 
bind to FGF10, which is highly expressed in AT and has previously been described to 
modulate preadipocyte differentiation128. Consequently, we cloned the two predicted miR-
327 binding sites in the 3’UTR of Fgf10 into a dual luciferase reporter vector and measured 
luciferase activity in the presence of miR-327. A significant reduction of luciferase signals 
could be measured for both binding sites, and specific point mutations of the binding site 
hindered miR-327 from binding, thereby preventing miR-327 mediated repression of 
luciferase signals. These data confirm that miR-327 has two binding sites in the 3’UTR of 
Fgf10 mRNA. Extraction of FGF family members from a microarray conducted with 3-day 
CL treated visWAT SVFs compared to vehicle control confirmed that Fgf10, as well as its 
receptor Fgfr2, were upregulated upon early browning of WAT. Considering the mode of 
action of miRNAs, the analysis of mRNA expression levels does not fully reflect their 
repressive potential. Therefore, we performed western blot analysis to define FGF10 protein 
levels in scWAT, visWAT and iBAT. Interestingly, protein levels of FGF10 in scWAT and 
visWAT were extremely low at thermoneutral temperatures and increased considerably after 
CL treatment or cold exposure. FGF10 could be detected in all samples from iBAT but did 
not change markedly upon adrenergic stimulation. These findings indicate an important 
function of FGF10 during WAT browning. 
To pinpoint which cells in the SVF express Fgf10, CD45+ immune cells, CD31+ vascular 
ECs, PDGFR-α+ stromal fibroblasts, and PDGFR-α- cells were isolated by magnetic cell 
sorting and expression levels of Fgf10 was measured. Fgf10 was almost exclusively produced 
by PDGFR-α+ stromal fibroblasts, a cell type with the capacity to differentiate into ACs. 
Fgfr2 and miR-327 showed similar, however less specific, expression patterns with the 
highest expression measured in PDGFR-α+ cells. These data suggest an autocrine regulatory 
loop where levels of miR-327 control protein levels of FGF10 and thereby FGFR2 mediated 
downstream tyrosine kinase signaling in PDGFR-α+ cells. To confirm this initial hypothesis, 
we treated 3T3-L1 preadipocytes with miR-327 mimics and inhibitors. FGF10 levels were 
markedly reduced after miR-327 mimic treatment and increased after treatment with a miR-
327 inhibitor. Furthermore, miR-327 mimic treatment resulted in decreased phosphorylation 
of the downstream FGFR2 mediators FGFR substrate 2-alpha (FRS2-α) and Akt, but not Erk. 
These findings confirm that miR-327 targets FGF10 and blocks FGF10-induced FGFR2-Akt 
signaling. Following the general notion that Akt phosphorylation is important for 
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preadipocyte differentiation149, we performed a differentiation assay with 3T3-L1 
preadipocytes and primary preadipocytes isolated from scWATs. In both cases, miR-327 
mimic administration resulted in a great inhibition of preadipocyte differentiation potential 
where only a very low number of lipid-loaded ACs could be detected in the mimic treated, 
compared to control treated samples. Inhibition of miR-327, on the other hand, resulted in a 
significant increase in preadipocyte differentiation and lipid deposition. We further measured 
differentiation markers in primary preadipocytes and differentiated WA treated with miR-
327 mimics. All differentiation markers were drastically reduced in mimic treated samples. 
Furthermore, analysis of browning markers was performed after differentiation of miR-327 
mimic treated cells with or without 4h isoproterenol stimulation to activate uncoupling in 
these cells. Consistent with previous results, browning markers were significantly less 
expressed in mimic treated cells compared to controls. 
To further define the role of miR-327, FGF10, FGFR2 and downstream Akt signaling in the 
regulation of preadipocyte differentiation, we performed preadipocyte differentiation assays 
with 3T3-L1 cells under a variety of conditions. First, we conducted a rescue experiment, 
where we applied recombinant FGF10 to miR-327 mimic treated cells. Exogenously applied 
FGF10 allowed these cells to differentiate into ACs in greater numbers. However, if FGFR2 
was blocked or Akt was inhibited simultaneously, cells failed to differentiate. This indicates 
that FGF10 acts through the FGFR2-Akt pathway to induce differentiation. Loss of function 
experiments revealed that knockdown (KD) of Fgf10 completely blocked differentiation and 
simultaneous treatment with the miR-327 inhibitor failed to rescue this phenotype. The 
addition of conditioned medium from control or miR-327 inhibitor treated cells, however, 
enabled cells to differentiate similar to untreated cells. These data verify that FGF10 is crucial 
for adipocyte differentiation and that extracellular FGF10 is the key mediator. Next, we 
checked the influence of FGF10 and miR-327 levels on preadipocyte proliferation at different 
time-points during the differentiation process. 3T3-L1 preadipocytes were treated with 
FGF10 recombinant protein, siFgf10, miR-327 mimic or miR-327 inhibitor, but none of these 
treatments resulted in altered proliferation. SiFgf10 and miR-327 mimic treatment blocked 
differentiation, therefore some proliferative preadipocytes could be detected at day 6 of 
differentiation, whereas other groups were already terminally differentiated. These data 
confirm that FGF10 levels have no effect on preadipocyte proliferation. 
To validate if increased levels of miR-327 can modulate WAT browning in vivo, miR-327 
expressing adenovirus was directly injected into scWAT and visWAT of immunodeficient 
NSG mice, followed by CL treatment or cold exposure. In both cases, excessive amount of 
miR-327 lead to increased adipocyte size and a decrease in mitochondrial number and 
uncoupling. Additionally, FGF10 protein levels were drastically decreased in CL and 4 °C 
treated scWATs overexpressing miR-327. Furthermore, increased scWAT mass, reduced 
oxygen consumption, attenuated NE-induced thermogenesis and lower core body 
temperatures could be detected in mice with increased miR-327 levels upon cold exposure. 
To characterize systemic effects of miR-327 inhibition, we injected a miR-327 inhibitor to 
C57/Bl6 mice. Interestingly, FGF10 protein levels were highly elevated in 30 °C exposed 
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mice, which demonstrated reduced adipocyte size and increased numbers of mitochondria 
and augmented UCP1 levels. Exposure to cold temperatures in combination with miR-327 
inhibition resulted in robust browning, increased mitochondrial staining and Ucp1 
expression. Furthermore, increased energy expenditure and NE-induced thermogenesis could 
be detected in 30 °C and 4 °C exposed mice treated with miR-327 inhibitor. To validate if 
this effect is dependent on FGF10, we additionally injected miR-327 inhibitor into Fgf10+/- 
mice. Compared to WT mice, miR-327 inhibitor effects were drastically reduced and only 
slight changes in adipocyte size could be detected. FGF10 and UCP1 levels were barely 
detectable and no changes in scWAT weight, body temperature or energy expenditure were 
observed. Since the miR-327 inhibitor was applied systemically, we additionally analyzed 
BAT activation and FGF10 levels in all inhibitor studies, however, could not detect any 
effects of miR-327 inhibition on iBAT. 
Based on the collected evidence in this publication, we believe that miR-327 regulates FGF10 
production in PDGFR-α+ preadipocytes under physiological conditions. Cold exposure or 
similar adrenergic stimulation reduces miR-327 levels, resulting in increased levels of FGF10 
that can act in an autocrine fashion to activate FGFR2-Akt signaling, resulting in beige 
adipocyte differentiation. 
 
3.2 PAPER II: ABLATION OF ENDOTHELIAL VEGFR1 IMPROVES 
METABOLIC DYSFUNCTION BY INDUCING ADIPOSE TISSUE 
BROWNING 
Adipocytes produce important secretory factors such as VEGF that are crucial to switch on 
angiogenesis105,150. While the interaction of VEGF with VEGFR2 has been intensively 
characterized in the AT, how binding of VEGF to VEGFR1 effects angiogenesis and AT 
metabolism is less understood; controversial findings in diverse studies make it difficult to 
draw general conclusions107,151.  
We utilized various pharmacological and genetic approaches to block VEGFR1 or delete the 
VEGFR1 gene globally or in specific cell types such as EC, AC and myeloid cells to clarify 
some of these controversies. Systemic VEGFR1 blockade or deletion resulted in robust 
angiogenesis and a browning phenotype in the AT. EC specific KO of VEGFR1 was sufficient 
to generate a similar phenotype as seen in global VEGFR1 KO mice and protected the mice 
from DIO. On the contrary, conditional KO of VEGFR1 in AC and myeloid cells failed to 
induce angiogenesis and no changes in adipocyte size and activation could be detected. Our 
data strongly suggests that the deletion or inhibition of VEGFR1 in ECs modulates adipocyte 
metabolism and provides an appealing novel mechanism for the treatment of obesity and 
related diseases such as liver steatosis and T2DM. 
Our study design is based on the initial finding that blockade of VEGFR1 induces angiogenesis. 
Indeed, 10-day anti-VEGFR1 treatment of C57/Bl6 mice resulted in a robust activation of 
  23 
angiogenesis in scWAT, visWAT and iBAT1. Furthermore, vessel integrity could be confirmed 
by the quantification of vessel perfusion and leakiness. VEGFR1 has three ligands, VEGF, 
VEGF-B and PlGF. Expression analysis of these three factors after anti-VEGFR1 treatment 
demonstrated an increased level of Vegfa, suggesting that VEGF is the driver of angiogenesis 
upon VEGFR1 blockade. Consequently, we performed some combination studies where 
VEGF or VEGFR2 were blocked in combination with VEGFR1 blockage. Both VEGF and 
VEGFR2 neutralization fully reversed VEGFR1 induced angiogenesis. Furthermore, we could 
demonstrate that VEGFR1 blockade increases VEGFR2 phosphorylation, further suggesting 
VEGFR2 as the mediator of angiogenesis upon VEGFR1 inhibition. The effect of anti-
VEGFR1 induced angiogenesis on ATs was a reduction in AC size and an increase in non-
shivering thermogenesis. Both effects could be reversed by simultaneous blockade of VEGF 
or VEGFR2. A time-course experiment in 1-, 2-, 4-, 7- and 10-day anti-VEGFR1 treated 
animals demonstrated, that vessel numbers were significantly increased as early as treatment 
day 2, however, UCP1 expression levels and adipocyte size were not significantly altered until 
after the angiogenic period of 7 days. Therefore, we conclude that angiogenesis precedes AT 
alterations when VEGFR1 is blocked. 
To strengthen our findings, we performed additional analyses of AT in tamoxifen-inducible 
VEGFR1 KO mice (Fltf/f; Rosa26-Cre-ERT2). Similar to the pharmacological data, 10 days 
after KO induction: 1) vessel numbers were drastically increased; 2) EC proliferation could be 
detected; 3) AC size was reduced; and 4) non-shivering thermogenesis was increased in both 
white and brown ATs. Due to the broad expression of VEGFR1 in different cell types152, EC 
specific VEGFR1 KO mice were generated, Fltf/f; Tie2-Cre-ERT2 and Fltf/f; Cdh5-Cre-ERT2. 
We used two different KO models because Tie2 expression has been reported in glial cells in 
addition to ECs153. To exclude any effects generated by non-ECs, we extended our analysis 
with the more specific Cdh5-Cre strain. After tamoxifen induction, VEGFR1 expression was 
reduced to about 1/3 of the initial expression in isolated ECs. Both KO strains showed similar 
activation of angiogenesis and AC browning as the systemic KO mice. We extended our 
investigation on Fltf/f; Cdh5-Cre-ERT2 mice by treating them with CL and could demonstrate 
that loss of VEGFR1 in EC augments angiogenesis and thermogenesis in scWAT, visWAT 
and iBAT. Additionally, Fltf/f; Cdh5-Cre-ERT2 mice displayed resistance to DIO as evident in 
the metabolic analysis following HFD feeding. EC specific VEGFR1 KO mice had a similar 
food intake as WT mice, however less body weight and decreased scWAT, visWAT and iBAT 
fat weight. Moreover, blood parameters such as free fatty acids, glycerol, cholesterol, 
triglycerides, glucose and insulin were notably reduced, resulting in improved glucose 
tolerance and rapid glucose clearance in EC-VEGFR1 KO mice. Moreover, lipid staining of 
the liver revealed a reduction of ectopic lipid storage in hepatocytes. Essentially, loss of 
VEGFR1 in EC ameliorates dysfunctions in lipid and glucose metabolism and decreases lipid 
                                                 
1 To simplify, scWAT, visWAT and iBAT are used in the thesis text to define the three analysed adipose tissues, 
although different nomenclatures might have been used in the original scientific publications. 
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deposition in the liver, revealing the potential of blocking VEGFR1 for the treatment of T2DM 
and fatty liver disease.  
To exclude the contribution of additional VEGFR1 expressing cell types to adipocyte 
browning, we further deleted VEGFR1 in ACs (Fltf/f; Adipoq-Cre) and myeloid cells (Fltf/f; 
LysM-Cre). Neither of these mouse strains exhibited an increase in angiogenesis, AC browning 
or thermogenesis. Furthermore, we did not see any increase in macrophage number in Fltf/f; 
Cdh5-Cre-ERT2 mice treated with CL. Therefore, we conclude, that VEGFR1 KO in EC, not 
ACs or immune cells, influences angiogenesis and thereby modulates AT function. 
In summary, the findings in this publication support the notion that VEGFR1 acts as a decoy 
receptor for VEGF. During homeostasis, only a fraction of VEGF binds to VEGFR1 with 10-
fold higher affinity than VEGFR2. VEGF-VEGFR1 complexes result in relatively weak 
tyrosine kinase activation and thereby limit angiogenic potential in EC. Under such conditions, 
ATs are primed for energy deposition. Loss of VEGFR1 or blockade of the VEGFR1 binding 
site, on the contrary, allows a greater number of VEGF ligands to bind to VEGFR2, thereby 
transducing robust angiogenic signals. Proliferating EC secrete paracrine factors that trigger 
white ACs to take on a beige phenotype and induce mitochondrial uncoupling in BAs - 
resulting in increased energy expenditure. 
 
3.3 PAPER III: ENDOTHELIAL PDGF-CC REGULATES ANGIOGENESIS-
DEPENDENT THERMOGENESIS IN BEIGE FAT 
The AT is an extremely plastic organ that can adapt quickly to extrinsic stimuli such as 
increased need to store lipids, elevated energy requirements or an increased need of the body 
to produce heat. The alterations in AC during these processes have been well characterized, 
however, how non-vascular cells are affected during these processes is poorly understood. A 
number of studies demonstrated that both AC expansion and adipocyte activation alter the cell 
composition in the AT – especially the number of vessels and vessel-associated cells (reviewed 
in71 and67). Especially, induction of a beige phenotype in AC by β3-adrenergic stimulation or 
cold temperatures results in a drastic increase in blood vessels in the AT62. We could previously 
show that VEGF-VEGFR2 signaling is a key angiogenic stimulus during this process and is 
required for the induction of a brown-like phenotype in AC in vivo154. Despite this body of 
work, how these newly formed vessels interact with ACs to increase the number of beige ACs 
is not yet understood. 
In this study we performed microarray analysis of the adipose SVF, which includes all cells of 
the AT except ACs. When looking closely at the expression pattern of growth factors present 
in the SVF during browning, we identified Pdgfc as one of the main factors upregulated during 
adrenergic stimulation. The PDGF family shares structural and functional similarities to the 
VEGF family and has previously been demonstrated to be important for preadipocyte 
differentiation. PDGFR-α is strongly expressed on preadipocytes that can give rise to white, 
beige and brown AC116. 
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In this paper we aimed to identify the cellular source of PDGF-CC during browning and its 
effect on preadipocyte differentiation and activation. Performing in vivo gain- and loss-of-
function experiments as well as cell specific mRNA expression profiling, we could demonstrate 
that ECs are the source for PDGF-CC during adrenergic stimulation. Both blockade and 
induction of VEGF signaling controlled endothelial PDGF-CC production. Loss of PDGF-CC 
did not alter vessel number or angiogenesis during browning, however, decreased beige AC 
numbers and non-shivering thermogenesis. Similarly, induction of PDGF-CC expression had 
no effect on vessel numbers, however induced a brown-like phenotype in WATs. Therefore, 
we conclude that EC derived PDGF-CC is an important mediated of vessel-AC communication 
that has an essential function during AC browning. 
In our study, we first investigated angiogenic response in the visWAT of CL treated C57/Bl6 
mice by performing a time-course experiment. Blood vessel numbers were significantly 
increased already 2 days after the first CL injection and tripled within 10 days of treatment. 
VEGF levels more than doubled within one day of treatment and remained high for around 5 
days, further strengthening previous findings that angiogenesis is VEGF dependent during the 
browning process. To exclude any off-target effects of CL, we used β3-adrenoceptor KO mice 
and could confirm that CL does not cause any alterations in vessel number in these mice. In 
addition, cold exposure failed to activate browning and angiogenesis in visWAT, however, 
robust effects were observed in scWAT and iBAT. These data suggest that cold exposure was 
not sufficient to stimulate browning and angiogenesis in the visWAT in this particular 
experimental set-up. Accordingly, we used CL treatment for all further experiments.  
To validate if angiogenesis is dependent on mitochondrial uncoupling, we used Ucp1-/- mice. 
While browning was significantly reduced in these animals, no differences in Vegf expression 
levels or vessel number were detected. By blocking VEGF signaling, we attempted to further 
specify its role in CL-induced angiogenesis and browning. We utilized specific neutralizing 
antibodies against VEGF and VEGFR2 and a VEGFR tyrosine kinase inhibitor (Sunitinib). All 
three agents significantly suppressed angiogenesis and thermogenesis in CL treated mice, 
further highlighting the importance of VEGF signaling during browning. In addition to the 
previously mentioned pharmacological approaches we generated inducible, EC-specific 
VEGFR2 KO mice and treated them with CL. Similar to previous data, both mouse strains 
exhibited a decline in angiogenesis and AC browning. Furthermore, we generated a gain-of-
function model by transfecting either visWAT or scWAT with an adenovirus containing Vegfa 
and a GFP reporter construct. Local Vegfa overexpression alone could induce vessel number 
and browning in both visWAT and scWAT and even significantly increased oxygen 
consumption in mice when scWAT was transfected with the adenovirus. This demonstrates 
that both induction and reduction of angiogenesis has a substantial effect on WA activation and 
thermogenesis.  
To get further insight into the mechanism by which angiogenesis modulates AC function we 
performed microarray analysis of visWAT SVFs of CL treated animals to look at upregulated 
secretory factors. PDGF-CC was found to be the most upregulated gene upon all growth factors 
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and cytokines, which could be confirmed with qPCR analysis. Subsequent in vivo loss-of-
function and gain-of function experiments were conducted utilizing Pdgfc-/- mice and an 
adenovirus overexpressing Pdgfc. Pdgfc-/- mice showed no obvious phenotype and similar 
vessel numbers and non-shivering thermogenesis compared to WT mice. Upon CL treatment, 
however, an increase in AC size and a decrease in browning and mitochondrial marker 
expression could be detected, resulting in impaired non-shivering thermogenesis in browning 
WATs of Pdgfc-/- mice. Adenovirus-mediated, local delivery of PDGF-CC to visWAT and 
scWAT, could rescue this phenotype and resulted in an increase in the expression of beige AC 
markers and thermogenesis. These data validate that, upon adrenergic stimulation, EC derived 
PDGF-CC regulates thermogenesis in WATs downstream of VEGFR2-induced angiogenic 
signals. 
In a DIO model, both Vegf and Pdgfc expression levels were markedly reduced. Therefore, we 
investigated if the positive effect of PDGF-CC on WA browning could be translated to obese 
settings. Indeed, adenovirus-induced local overexpression of Pdgfc in visWAT and scWAT of 
obese mice resulted in reduced fat mass and accelerated glucose clearance. PDGF-CC mainly 
binds to PDGFR-α to transduce downstream signals. We could show that PDGFR-α expression 
is increased in CL-treated visWAT and that PDGFR-α expression does not overlap with CD31 
EC expression, indicating that non-EC in the AT increase the receptor expression during 
browning. We further isolated PDGFR-α+ cells from WATs from both, human and mice, and 
treated them with recombinant PDGF-CC. Upon differentiation, higher levels of UCP1 and 
other browning factors were detected. In vivo loss-of-function studies utilizing PDGFR-α and 
PDGFR-β neutralizing antibodies reflected less browning and inhibition of non-shivering 
thermogenesis in CL treated mice especially upon PDGFR-α inhibition.  
In summary, we could demonstrate that VEGF-VEGFR2 interaction and induction of 
angiogenesis is necessary to activate white ACs to adapt a brown-like phenotype. These 
angiogenic ECs produce PDGF-CC, which binds to PDGFR-α on preadipocytes and drives 
their differentiation into beige AC. 
 
3.4 PAPER IV: MODULATION OF AGE-RELATED INSULIN SENSITIVITY BY 
VEGF-DEPENDENT VASCULAR PLASTICITY IN ADIPOSE TISSUES  
Age is a major risk factor for obesity and secondary diseases such as T2DM, cardiovascular 
disease, hypertension and certain types of malignant diseases. Both incidence of obesity and 
diabetes is highest in middle aged individuals between around 40-60 years of age155,156. 
Although correlated to the BMI, the significant increase of T2DM prevalence in middle-aged 
individuals cannot be fully explained by increased body weight. One age-related risk factor for 
T2DM is the decline of pancreatic islet function and proliferative capacity157. Additionally, a 
large body of evidence suggest that metabolic abnormalities cause overproduction of reactive 
oxygen species that in turn lead to EC dysfunction, inflammation and diabetic vascular 
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disease158. There is, however, limited information on the role of the vascular network during 
the onset of diabetes.  
In this paper, we provide evidence that vascular plasticity fluctuates with age and show that 
this is occurring in a VEGF-dependent manner. These fluctuations correlate with the risk of 
developing T2DM. We could further demonstrate that anti-VEGF treatment increases insulin 
sensitivity in age groups with high vascular plasticity and DIO mice. The first part of the study 
focuses on AC morphology and vessel number in different age groups. We chose C57Bl/6 mice 
of ages 1, 4, 10, 12 and 16 months, which corresponds to 4-, 17-, 42-, 50-, and 70-years in 
humans. We analyzed scWAT, visWAT and iBAT in these mice to evaluate differences in the 
vasculature in this broad set of adipose depots. In scWAT, AC size increased with age in 
accordance with BMI (from 1 month to 10 months), in contrast to vessel density, which was 
negatively correlated with BMI. In older mice, BMI stabilized, although we could demonstrate 
a decrease of AC size and increase of vessel number in the 12-, and 16-month old groups. 
VisWAT followed a similar trend. Vessel numbers were high in young and old age groups and 
had a low-peak in middle-aged mice. AC size was, similar to scWAT, negatively correlated to 
the vessel numbers. The decrease of adipocyte size and increase of vessel numbers in older age 
groups, however, was less pronounced. Similar but generally milder alterations of AC size and 
vessel density were measured in iBAT. Interestingly, iBAT weight almost doubled during a 
mouse’s life span, Ucp1 expression, however, did not correlate with the increase in tissue mass. 
Therefore, we investigated expression levels of Ucp1 in iBAT and could confirm that less 
uncoupling protein was produced by iBAT in older age groups.  
To address the role of VEGF signaling on age-related alterations of the adipose vasculature, 
VEGF, VEGFR1 and VEGFR2 protein levels were studied in WATs and iBAT. In accordance 
with the histological data obtained, VEGF levels reached a low-point in middle-aged animals 
and increased again thereafter. We could further show that VEGFR1 levels peaked in 10-month 
old mice. This finding correlates with the notion that VEGFR1 function as a decoy receptor for 
VEGF. VEGFR2 was highly expressed in young mice and showed declining expression with 
age, suggesting high demands for angiogenesis in adolescent mice. To elucidate the effect of 
VEGF signal inhibition on aging ATs, we injected VEGF- and VEGFR2 neutralizing 
antibodies to 1-month, 7-month, and 15-month-old healthy mice.  1-month and 15-month old 
mice lost bodyweight upon treatment, leading to a significantly lower BMI compared to control 
animal. Vessel number was reduced significantly in all age groups; however, middle-aged mice 
displayed a rather moderate effect. Based on these findings, we concluded that ATs of middle-
aged mice are less dependent on VEGF signaling and therefore somewhat resistant to anti-
VEGF and anti-VEGFR2 treatment. Next, we asked the question if these age-related changes 
in adipose vasculature have systemic effects on metabolic parameters such as lipolysis and 
insulin sensitivity. Therefore, blood lipids, fasting glucose and insulin were determined. While 
only slight alterations in triglycerides, non-esterified fatty acids, glycerol, cholesterol and 
fasting glucose could be detected in the blood of healthy mice at different ages, we could 
monitor a drastic increase in circulating insulin levels in the 15-month old group, resulting in 
substantially reduced insulin sensitivity. HOMA-IR levels were 3-fold higher in 15-month old 
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mice compared to young and middle-aged mice, suggesting insulin resistance. We further 
analyzed these metabolic parameters in anti-VEGF treated animals of different ages. 
Interestingly, anti-VEGF treatment resulted in a decrease of fasting glucose levels in all age 
groups and a reduction in fasting insulin in older animals, improving HOMA-IR drastically 
and almost completely reversing the insulin resistance observed in the 15-month control 
animals. To further evaluate these findings, insulin tolerance tests (ITTs) were performed for 
all age groups. In accordance with previous results, adolescent and old mice could improve 
their glucose clearance upon VEGF blockade; middle-aged mice, on the contrary, showed no 
effect upon treatment. This finding further strengthens the observation that middle-aged 
animals are somewhat resistant to VEGF treatment and related metabolic effects. 
Considering the fact that insulin resistance is not only strongly linked to age, but also body 
weight, we generated DIO mice.  Middle-aged DIO mice were treated with anti-VEGF at 7-
month of age and were analyzed for histological as well as metabolic parameters. In contrast 
to lean mice, HFD fed middle-aged mice showed high sensitivity to anti-VEGF treatment 
leading to a drastic reduction in vessel numbers. Body weight, fat mass and fasting glucose 
levels were drastically reduced, and insulin sensitivity significantly increased. To determine 
the underlying cause of the increased responsiveness to anti-VEGF treatment and the increase 
in insulin sensitivity in DIO mice, we investigated macrophage number and cytokine 
production. In obese mice, macrophage number was increased, and anti-VEGF treatment 
further induced the expression of Il6 and Tnfα. It is, however, unlikely that increase of 
macrophage number and cytokine production would contribute to anti-VEGF induced insulin 
sensitivity, because induction of inflammation and the upregulation of both, IL-6 and TNF-α 
have previously been linked to the development of insulin resistance in DIO159,160. Therefore, 
we conclude that further investigations are necessary to pinpoint the mechanism that makes 
middle-aged DIO mice more sensitivity to anti-angiogenic treatment and insulin induced 
glucose uptake. 
Taking together, our data demonstrate age-related alterations in vessel number and metabolic 
activity, which results in altered sensitivity to anti-angiogenic treatment. Importantly, anti-
VEGF treatment leads to increased insulin sensitivity and glucose clearance in young and old 
mice, as well as middle-aged HFD fed animals. These findings give additional insight on how 
angiogenesis modulating agents can be used to treat obesity and T2DM. Further studies are 
however needed to clarify if increased or decreased vessel numbers in the AT are more 
beneficial for long-term treatment of obesity and related diseases. 
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4 CONCLUSION AND PROSPECTIVE 
Activation of BAT increases energy expenditure and might be a treatment option to reverse 
obesity and related diseases. If the activation of BAT alone is sufficient to reach this goal, is 
however still under debate. Beside BAT activation, additional WAT browning might be 
necessary to successfully increase whole-body energy expenditure to a clinically relevant 
level. In my thesis projects we aimed to: 1) activate WATs to take on a brown-like phenotype; 
2) make visWAT more susceptible to browning; 3) characterize the function of blood vessels 
in AT browning and aging; 4) define secretory factors that alter AC metabolism; and 5) 
identify regulatory mechanisms that alter the secretion of these factors. Altered proliferation 
and gene expression patterns in non-ACs including vessel associated cells and inflammatory 
cells have been described in both WATs and BAT67. We believe that a deep understanding 
of the cross talk and interaction between cells in the AT and their consequences on whole-
body metabolism will be essential to develop pharmaceuticals that can reverse metabolic 
disease and thereby help to generate a healthier population.  
Along with metabolic activation, vessel density and vessel-associated cell numbers are 
markedly increased in all ATs upon adrenergic stimulation62,161. This effect was originally 
thought to be a consequence of the increased energy needs of AC due to mitochondrial 
uncoupling162. Recent studies from our laboratory, however, demonstrate that vessel numbers 
even increase in Ucp1 KO mice treated with cold or adrenergic agonists, suggesting 
activation of angiogenesis independent of uncoupling62,163. We could further demonstrate that 
angiogenesis in the AT is VEGF dependent and time-course experiments indicated that as 
early as 2 day after induction of browning, VEGF levels are significantly increased62-64. 
Microarray analysis of 3d CL treated SVFs in the visWAT confirmed this finding and 
suggested the involvement of other growth factor families, such as FGF and PDGF, in AT 
browning63. These data exclude the possibility that mitochondrial uncoupling in ACs 
activates angiogenesis during early browning and suggest that blood vessel changes precede 
metabolic activation. Therefore, we speculated that in-depth analysis and modulation of these 
growth factors in a browning setting might aid in increasing metabolic activity in ATs and 
might further be responsible for an increased susceptibility of visWAT for browning, which 
in general is less responsive to adrenergic stimulation compared to scWAT. Indeed, two of 
the identified factors, PDGF-CC and FGF10, could induce WAT browning and loss of either 
of these factors resulted in diminished AC activation. Cell type specific expression patterns 
suggest further, that both of these growth factors act on PDGFR-α+ preadipocytes to drive 
them into beige ACs differentiation. Our data strongly suggest that angiogenesis is a 
prerequisite that is essential to induce beige adipocyte differentiation under adrenergic 
stimulation. 
Although we could see clear functional effects in vivo and strong increase in protein levels, 
microarray and qPCR analysis resulted in rather moderate changes in mRNA levels for some 
growth factors in whole tissue homogenates. Possible explanations are: 1) limited local but 
rather systemic production of these growth factors and delivery to the AT through the 
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vasculature, 2) alterations in protein stability, or 3) post-transcriptional control through 
miRNAs. MiRNA array analysis revealed that miRNA levels are indeed significantly altered 
in the SVF of 3d CL treated visWAT. MiRNA target analysis further confirmed that many 
of these miRNAs have predicted target sites in the 3’UTR of VEGF, PDGF and FGF family 
members. The strong reverse correlation between FGF10 and miR-327 expression in 
browning AT together with the fact that FGF10 is essential for WAT development127 
warranted us to ask if this miRNA has a regulatory function in WAT browning. We could 
demonstrate that miRNAs can play a role in WAT browning by controlling preadipocyte 
differentiation. In recent years, several RNAi-based therapeutics have been developed and 
the first miRNA-targeting drugs entered clinical trials (reviewed in164). Poor delivery and 
toxicity are, however, current challenges. Only future will tell if such obstacles can be 
resolved to bring miRNA targeting drugs to patients for the treatment of various diseases, 
including obesity. 
While the function of VEGF-VEGFR2 interaction is clearly defined in AT angiogenesis, 
binding and activation of VEGFR1 by VEGF, VEGF-B and PlGF is less well understood. In 
our studies we found that VEGFR1 is upregulated in middle-aged mice, which might explain 
the phenotype that ATs are less vascularized in this age group. Furthermore, we found that 
EC specific VEGFR1 KO is sufficient to induce VEGF-VEGFR2 dependent angiogenesis 
and to create a browning phenotype in WATs as well as a resistance against DIO. A related 
study conducted in Dr. Alitalo’s laboratory demonstrated that overexpression of VEGF-B 
produces a similar phenotype. This phenomenon is explained by the fact that VEGF binds 
with higher affinity to VEGFR1 than to VEGFR2, therefore, increased VEGF-B levels 
resulted in a higher number of VEGF-B-VEGFR1 complexes. This further allows VEGF to 
bind to VEGFR2 instead of VEGFR1107. Our work presented in this thesis and Dr. Alitalo’s 
study contradict however Dr. Jain’s study from 2009, which concluded that VEGFR1 
blockade does not affect body weight in HFD fed mice151. Another early study utilized PlGF 
KO mice, which showed reduced vessel numbers in AT and resistance to DIO165. We 
conclude that further studies on ligand specific differences in VEGFR1 downstream signaling 
are needed to fully explain VEGFR1 function in ATs. 
While increase in vessel numbers is crucial for AT browning, controversial results have been 
described in DIO models. VEGF TG166, VEGF-B overexpressing107 or VEGFR1 KO64 mice 
all have an increased amount of blood vessels in ATs and are resistant to DIO and fatty liver 
disease. On the contrary, blockade of VEGF167 or depletion of PlGF165 results in decreased 
vessel numbers, however, similar improvements in body weight and insulin sensitivity in 
DIO models could be measured. Other factors such as hypoxia, inflammation, age and genetic 
background might be of importance to explain why gain- and loss- of blood vessels in the 
AT can protect against DIO and further studies are needed for clarification. 
So, where do we currently stand and where is the future heading? Findings presented in our 
works give important insides in the communication between blood vessel associated cells 
and ACs and demonstrate a strong link between PDGF, FGF and VEGF signaling 
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components and AT function. This work suggests several novel strategies for the treatment 
of obesity and metabolic diseases, including posttranscriptional modulation by miRNAs. We 
hope that some of the novel targets provided through our research will lead to the delevopment 
of therapies that improve the quality of life for patients suffering from obesity and related 
secondary diseases. 
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